Follow-Up Care After Rapid ART Initiation

HIV Monitoring and Treatment

• The American Academy of HIV Medicine recommends measuring HIV RNA level to assess early virologic response within 4-6 weeks of ART initiation 1, 2
• The HIV Medicine Association suggests assessing medication adherence and tolerability of the ART regimen within 4-6 weeks of initiation 1, 2, 3
• The Centers for Disease Control and Prevention recommend evaluating for adverse effects, including any drug-related toxicity, within 4-6 weeks of ART initiation 1
• HIV RNA suppression may occur faster with integrase strand transfer inhibitor (InSTI)-based regimens, but can take up to 24 weeks 2, 4
• The Department of Health and Human Services recommends HIV RNA monitoring every 3 months until viral suppression below 50 copies/mL is achieved and maintained for at least 1 year 1, 2, 3
• The World Health Organization suggests HIV RNA monitoring every 6 months thereafter if the patient remains virologically suppressed, clinically stable, and adherent 1, 2, 3
• If HIV RNA has not declined considerably by 4-6 weeks and adherence is adequate, genotypic resistance testing should be performed, as recommended by the International AIDS Society 2
• CD4 cell count monitoring is recommended every 6 months until CD4 count is consistently above 250 cells/μL for at least 1 year with concurrent viral suppression, according to the European AIDS Clinical Society 1, 2
• Routine CD4 monitoring can be discontinued after 1 year of CD4 >250 cells/μL, unless virologic failure occurs or immunosuppressive conditions develop, as suggested by the British HIV Association 1, 2
• Confirmed HIV RNA >200 copies/mL on at least 2 consecutive measurements defines virologic failure, according to the National Institutes of Health 5
• If HIV RNA >50 copies/mL is detected after previous suppression, repeat measurement within 4 weeks and reassess adherence, as recommended by the AIDS Clinical Trials Group 2, 5

Additional Screening and Monitoring

• The Centers for Disease Control and Prevention recommend screening for other sexually transmitted infections at all exposed mucosal sites (pharyngeal, urethral, rectal as appropriate) 1
• The American College of Physicians suggests hepatitis C screening annually for men who have sex with men with ongoing risk 2
• The US Preventive Services Task Force recommends age- and risk-appropriate cancer screening, including anal and cervical dysplasia screening 1, 2
• The Infectious Diseases Society of America recommends assessing for opportunistic infections if CD4 count was initially low 1
• Renal function monitoring (creatinine, estimated GFR) is recommended, particularly if using tenofovir-containing regimens, according to the National Kidney Foundation 1
• Liver function tests are recommended at baseline and as clinically indicated, as suggested by the American Association for the Study of Liver Diseases 1
• Lipid panel is recommended for cardiovascular risk assessment, according to the American College of Cardiology 1
• Complete blood count is recommended to monitor for hematologic toxicity, as suggested by the American Society of Hematology 1

Critical Pitfalls to Avoid

• Do not delay follow-up beyond 6 weeks for initial viral load assessment, as early identification of inadequate response allows for timely intervention, according to the HIV Medicine Association 1, 2
• Do not switch ART based on single detectable viral load without confirmation—isolated blips do not constitute virologic failure, as recommended by the International AIDS Society 5
• Do not continue CD4 monitoring indefinitely once sustained suppression and immune reconstitution are achieved, as this adds unnecessary cost without clinical benefit, according to the European AIDS Clinical Society 1, 2
• Do not order resistance testing for viral loads <200 copies/mL, as amplification is unlikely to succeed and does not meet the threshold for confirmed failure, as suggested by the AIDS Clinical Trials Group 5